Working… Menu

The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03304288
Recruitment Status : Active, not recruiting
First Posted : October 9, 2017
Last Update Posted : January 20, 2021
Beijing Hospital
Navy General Hospital, Beijing
Beijing Tongren Hospital
Information provided by (Responsible Party):
Xiao-hui Zhang, Peking University People's Hospital

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : January 15, 2021
Estimated Study Completion Date : February 28, 2021